This tenth issue of our DDup (Drug Discovery Update) is dedicated to our newly developed next generation predictive toxicology platform, a truly translational project across different groups at Evotec. Historically, Evotec has a longstanding expertise in in vitro toxicology through its wholly owned subsidiary Cyprotex and is now successfully combining this knowledge with our new and pioneering high-throughput transcriptomics platform and proprietary data analysis platform PanHunter^®, to provide a smart and forward looking solution in safety liability prediction.

Learn more about Evotec's predictive toxicology platform, read an interview with out toxicology and transcriptomics experts and more in this Panomics Drug Discovery update #10.